Eli Lilly second-quarter GLP-1 sales top analyst expectations
Investor's Business Daily reports the incretin franchise drove the beat, without detailing segment figures in the available item.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: Investor's Business Daily
The wire
- 01Investor's Business Daily reports Eli Lilly's second-quarter results came in above sales expectations, attributing the beat to its GLP-1 medicines.
- 02Incretin revenue trends shape supply allocation, pricing moves and the commercial pressure that flows through to telehealth and compounding channels.
- 03No revenue figures, product splits or guidance are given in the item; readers should check Lilly's own quarterly filing for the underlying numbers.
From the source
Read at investors.comLilly's GLP-1 Drugs Just Blew Sales Expectations Out Of The Water
